Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials
- 686 Downloads
Antipsychotic drugs are widely used as a first-line pharmacological approach to treat dementia-related psychiatric symptoms. However, in this population of patients, such drugs have been associated with severe safety concerns. Hence, the aim of this review is to asses systematically the efficacy of second-generation antipsychotics (SGAs) in treating dementia-related neuropsychiatric symptoms in order to establish if the potential clinical benefits of such treatment outweigh the hypothesised risks related to pharmacological intervention.
The Cochrane Library, MEDLINE, EMBASE and PsycINFO were searched (from 1980 to June 22, 2010) using terms for included drugs (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, SGAs) and indications (elderly, dementia, Alzheimer's disease). Electronic database search were supplemented with hand search of references lists of electronically identified articles. Peer-reviewed, randomised, controlled trials published in English and investigating the efficacy of SGAs in patients with different forms of dementia were included in the review process. Information was drawn from the 30 articles that met the inclusion criteria.
Nearly all reviewed studies suffer from methodological limitations too severe to draw definitive conclusions that may inform the decision-making process. Moreover, studies conducted with similar methodological design show conflicting efficacy results.
Because of their undemonstrated effectiveness, SGAs should be avoided in patients with dementia complicated by psychotic and/or behavioural symptoms. Hence, further researches are urgently needed to identify useful pharmacological strategies that can be used to improve the clinical condition of such patients and to reduce burden to caregivers when behavioural interventions are ineffective.
KeywordsDementia Neuropsychiatric symptoms Second-generation antipsychotics Alzheimer Behavioural symptoms
Dr. Gentile acknowledges Medical Information Service (Annamaria Desiati, Lucia Fantini, Luana Salvati), a free-access service of Eli Lilly SpA, Sesto Fiorentino, Italy, for the kind and professional support in providing full-text articles. Dr. Gentile also acknowledges Mr. Richard Stuart Harrison for his precious editorial assistance.
Disclosure of interests
Dr. Gentile has received speaker bureau/consultant honoraria by Boehringer Ingelheim and Eli Lilly Italia SpA. During the last 5 years, Dr. Gentile has also received travel funds by Bristol-Myers Squibb, Eli Lilly, Lundbeck and Novartis. No financial support for this study was received. No potential conflicts of interest are directly related to the subject of this paper.
- Alexopoulos GS, Stremi J, Carpenter D, Docherty JP (2004) Using antipsychotic agents in older patients. J Clin Psychiatry 65(Suppl 2):1–105Google Scholar
- Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of psychosis in Alzheimer's disease. Cochrane database Syst Rev Art. No: CD003746. doi: 10.1002/4651858.CD003476.pub2.
- Ballard C, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM et al (2004) A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cut-off is a predictor of clinical outcome. J Clin Psychiatry 65:114–119CrossRefPubMedGoogle Scholar
- De Deyn P, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al (2004) Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Ger Psychiatry 19:115–126Google Scholar
- Gentile S (2009) Second-generation antipsychotics in bipolar disorder, two years later: the song remains the same. Sociedad Iberoamericana de Información Cientifica www.siicsalud.com/des/expertocompleto.php/101621
- Katz IR, Jeste DV, Mintzer JE, Clyde C, Napoletano J, Brecher M, for the Risperidone Study Group (1999) Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomised, double-blind trial. J Clin Psychiatry 60:107–115CrossRefPubMedGoogle Scholar
- McGrath AM, Jackson GA (1996) Survey of prescribing in residents of nursing home in Glasgow. BMJ 314:611–612Google Scholar
- Mintzer JA, Tune LE, Breder CD, Swanick R, Marcus RN, McQuade RD et al (2007) Aripiprazole for the treatment of psychosis in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 15:918–931CrossRefPubMedGoogle Scholar
- Rosenhek RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS et al (2007) Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression inn Alzheimer disease. Arch Gen Psychiatry 64(11):1259–1268CrossRefGoogle Scholar
- Rossom RC, Rector TS, Lederle FA, Dysken MW (2010) Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc: In pressGoogle Scholar
- Schneider LS, Dagerman KS, Insel P (2006a) Efficacy and adverse events of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. J Am Geriatr Psychiatry 14:191–210Google Scholar
- Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, for the CATIE-AD Study group (2008) Clinical symptoms responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165:844–854CrossRefPubMedGoogle Scholar
- US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. US Food and Drug Administration, FDA Public Health Advisory, Centre for Drug Evaluation and Researches. http://www.fda.gov/Cder/drug/advisory/antipsychotics.htm. Accessed: February 21, 2008.
- Verhey FRJ, Verkaaik M, Lousberg R, on behalf of the Olanzapine-Haloperidol in Dementia Study Group (2008) Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results from a randomized controlled double-blind trial. Dement Geriatr Cogn Disord 21:1–8CrossRefGoogle Scholar